Becton Dickinson and (BDX) Earnings Date & Reports

Key Takeaways

• BDX reports fiscal fourth-quarter 2026 results, covering the period ended September 30, 2026, on Thursday, November 5, 2026, before the market opens.
• Analysts expect adjusted EPS (earnings per share) of roughly $4.07 on revenue near $5.11 billion, compared with $3.96 in EPS and $5.89 billion in revenue a year earlier.
• Becton, Dickinson has beaten consensus EPS estimates in eight consecutive quarters, a track record investors will be watching closely.
• Management previously narrowed its full-year fiscal 2026 adjusted EPS guidance to a range of $12.62 to $12.72, raising the midpoint.
• Key watch items include the Alaris infusion pump transition, vaccine demand, and persistent softness in the China market.
• For more information about BDX's Major News, Today's Price Move, Price Targets, and Forecast, explore our additional pages for deeper, data-driven insights.
• Looking for actionable trade ideas? Explore Trending AI Robots to discover AI-powered trading strategies across the market.

Earnings Context and Why It Matters

Becton, Dickinson and Company is one of the world's largest medical technology companies, and its fiscal fourth quarter is a pivotal reporting event because it closes out the full fiscal year and typically sets the tone for the company's forward guidance. Following the recent separation of its Life Sciences business, BDX now operates a more focused portfolio, making this quarter an important checkpoint on how the remaining businesses are performing. The report also tests management's ability to navigate three clearly identified headwinds: the Alaris infusion pump transition, softer vaccine demand, and weakness in China. With a long-running streak of consensus EPS beats, expectations heading into the print remain elevated.

Earnings Expectations

For the fiscal fourth quarter of 2026, Wall Street consensus calls for adjusted EPS of approximately $4.07 on revenue of about $5.11 billion, according to aggregated estimates. That compares with adjusted EPS of $3.96 on $5.89 billion in revenue in the same quarter a year ago. The year-over-year revenue comparison is affected by recent portfolio changes, including the Life Sciences separation, rather than reflecting a purely organic slowdown.

Investors will also weigh the quarter against full-year guidance. Management narrowed its fiscal 2026 adjusted EPS outlook to $12.62 to $12.72, raising the midpoint, which signaled confidence despite near-term pressures. In the prior quarter, BDX posted adjusted EPS of $3.23, exceeding the $3.14 consensus, on revenue of roughly $4.98 billion. Key metrics to watch include organic revenue growth by segment, gross margin trends, and any early color on fiscal 2027 guidance, which the company is expected to provide alongside these results.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical companion for earnings season research and beyond.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautiously optimistic. BDX has delivered consensus-beating earnings in eight straight quarters, and analysts have generally maintained a constructive tone on the company's margin potential and diversified portfolio. However, the stock enters this event with elevated expectations, which raises the bar for a positive reaction. The most significant risk factors include a sharper-than-expected impact from the Alaris transition, ongoing vaccine headwinds, and any deterioration in the China market. Investors will also be sensitive to the initial fiscal 2027 outlook, as management has indicated it will address guidance at this time. A beat paired with reassuring guidance would likely be viewed favorably, while any signals of delayed recovery in key growth platforms could temper enthusiasm.

Forward Outlook and Key Factors to Monitor

Looking beyond the fiscal fourth-quarter print, the market's attention will quickly shift to fiscal 2027. Management has signaled that the three main headwinds — Alaris, vaccines, and China — should begin to fade over the coming year. The Alaris impact, in particular, is expected to conclude in fiscal 2027, which could support a return toward mid-single-digit growth in the relevant businesses.

Investors should monitor the company's commentary on vaccine order patterns and any stabilization in China, where the business now represents a smaller share of revenue following the Life Sciences separation. Margin progression will also be a central theme, as productivity initiatives under the company's operating model are expected to offset some of the revenue pressures.

Finally, watch for updates on growth platforms such as pharmacy automation, biologics delivery, and connected medication management. These areas represent potential catalysts, but the company has cautioned against extrapolating unusually strong quarters in certain product lines. As always, the forward guidance will matter as much as the headline numbers.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations